Pentraxin 3: A promising Therapeutic Target for Cardiovascular Diseases

Ageing Res Rev. 2023 Dec 11:102163. doi: 10.1016/j.arr.2023.102163. Online ahead of print.ABSTRACTCardiovascular disease (CVD) is the primary global cause of death，and inflammation is a crucial factor in the development of CVDs. The acute phase inflammatory protein pentraxin 3 (PTX3) is a biomarker reflecting the immune response. Recent research indicates that PTX3 plays a critical role in CVDs and has been investigated as a possible biomarker for CVD in clinical settings. PTX3 is implicated in the progression of CVDs through mechanisms such as exacerbating vascular endothelial dysfunction, affecting angiogenesis, and regulating inflammation and oxidative stress. This review summarizes the structure and function of PTX3, focusing on its multifaceted effects on CVDs, such as atherosclerosis, myocardial infarction, and hypertension. This may help in explaining the varying PTX3 doses and usage, as well as in utilizing target organs to manage diseases. Moreover, elucidating the opposite role of PTX3 in the cardiovascular system will demonstrate the therapeutic and predictive potential in human diseases.PMID:38092307 | DOI:10.1016/j.arr.2023.102163
Source: Ageing Research Reviews - Category: Genetics & Stem Cells Authors: Source Type: research